The week of October 11 saw further Warning Letters issued to manufacturers and distributors of unapproved COVID therapeutics and diagnostics. This summary of Q2 food and dietary supplement Warning Letters includes a listing of such Warning Letters issued in that quarter.

On the pharma front, FDA issued an untitled letter to a manufacturer of umbilical cord-derived cell therapy products and a Warning Letter to a sterile manufacturing site in India.

Drug Warning and Untitled Letters

  • Optimal Health Stem Cell and Wellness Institute dba OSHTEMCELL (Appleton, WI) received an untitled letter from CBER on October 1, 2020, based on a review of social media pages and the company website. The firm markets umbilical cord-derived cellular products to treat a variety of diseases and conditions. These products are deemed to be HCT/Ps and thus regulated by FDA. Yet another enforcement action against these types of products.
  • Shilpa Medicare in Telangana, India announced that they received a Warning Letter on October 9, 2020. This is not yet posted on the FDA website. The form 483 the firm received in February 2020 that likely precipitated the official action mentions a number of CAPA failures, inadequate investigations, and failure to resolve customer complaints (notably all complaints since 2017 were labeled as “minor”). To access our database of form 483s, click here. If you’re not a customer, learn more about how to access our unmatched collection of 483 data.

Device Warning and Untitled Letters

There were none this week.

BIMO, GCP and GLP Warning and Untitled Letters

There were none this week.

Compounding Pharmacy/Outsourcing Facilities

There were none this week.

Redica Systems Enforcement Analytics

Get Full Access to Redica Enforcement Analytics

Enter your email address and someone will contact you shortly to answer all of your questions and get you started.

Quality Management Systems for Small Pharma and Biotech Firms

Webinar: QMS for Small Pharma and Biotech Firms

Presented on Tuesday, March 30, 2021
by Fenton Fong, Founder, Managing Director, & Principal at xCellarate

Download the slide deck and video of this informative 1-hour webinar on the common challenges small pharma firms face when developing a QMS.

What you will learn:

  • Common challenges small pharma firms face when developing a QMS
  • Recent enforcement trends involving the Quality Unit
  • Impact of the COVID-19 pandemic

Download the Special Report


In this summary we identify:

GMP data from FY2017 to FY2020 for the Asia-Pacific region

Top 3 GMP primary and secondary citations

Top 3 483 observations

Download the Special Report

An Analysis Of MHRA’s Latest Annual GMP Inspection Deficiencies Report

In this summary we identify:

  • Data from 2019 UK MHRA Inspections
  • Trends from 2015, 2016, 2018, and 2019 inspections
  • Conclusions drawn from an analysis of drug inspection data

Experience the Power of Redica Systems

Redica Pro Free

Sign up for your FREE account today and get instant access to:

SEARCH Find the inspection records you want by inspector’s name, company name, site, city, country, etc.

WARNING LETTERS Easily search the largest database of FDA Warning Letters by date, company, FDA office, or subject

SITES Quickly assess inspection records including dates and inspectors across all of your sites

INSPECTIONS Complete list of FDA inspections by date, company, category, and country

Get Complete Access to the Redica Systems Platform

Please submit your email address and one of our team members will contact you shortly to answer all of your questions and get you started with the new Enforcement Analytics platform.

Discover the power of the most comprehensive database of 483s in existence.

Our database of over 20,000 483s is retyped and tagged, making it easy to create an Observation Report in seconds.

Eliminate days of work and get your FREE personalized 483 Observation Report.